- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05159245
Finská národní studie k usnadnění přístupu pacientů k cíleným protirakovinným lékům (FINPROVE)
Finská národní studie, která má pacientům usnadnit přístup k cíleným protirakovinovým lékům ke stanovení účinnosti léčby pokročilých rakovin se známým molekulárním profilem
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Přehled studie
Postavení
Detailní popis
This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
- Jméno: Tanja Juslin
- Telefonní číslo: +358405597415
- E-mail: tanja.juslin@hus.fi
Studijní místa
-
-
-
Kuopio, Finsko
- Nábor
- Kuopio University Hospital
-
Kontakt:
- Okko Kääriäinen, MD
-
Oulu, Finsko
- Nábor
- Oulu University Hospital OYS Cancer Center
-
Kontakt:
- Sanna Iivanainen, MD. PhD.
-
Tampere, Finsko
- Nábor
- Tampere University Hospital Department of Oncology
-
Kontakt:
- Minna Tanner, MD, PhD
-
-
Southwest Finland
-
Turku, Southwest Finland, Finsko
- Nábor
- Turku University Hospital Cancer Centre
-
Kontakt:
- Erika Alanne, MD, PhD
-
-
Uusimaa
-
Helsinki, Uusimaa, Finsko, 00029
- Nábor
- Helsinki University Hospital Comprehensive Cancer Center
-
Kontakt:
- Tanja Juslin
-
Vrchní vyšetřovatel:
- Katriina Jalkanen, MD, PhD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.
-
ECOG performance status 0-2
-
Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:
- Absolute neutrophil count ≥ 1.5 x 109/l
- Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
- Platelets > 75 x 109/l (not applicable for hematological patients)
- Total bilirubin < 1.5 x ULN
- AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
-
Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.
-
Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.
-
Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.
-
A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.
-
Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.
Exclusion Criteria:
-
Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.
-
Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:
- Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
- Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
-
Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention
-
Patient is pregnant or nursing.
-
Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible
-
Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible
-
Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Alectinib
For patients with a molecular tumor profile that can potentially be targeted by alectinib. |
ALK
Ostatní jména:
|
|
Experimentální: Cobimetinib
For patients with a molecular tumor profile that can potentially be targeted by cobimetinib. |
MEK1, MEK2
Ostatní jména:
|
|
Experimentální: Vismodegib
For patients with a molecular tumor profile that can potentially be targeted by vismodegib. |
Hedgehog
Ostatní jména:
|
|
Experimentální: Trastuzumab+Pertuzumab
For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination. |
HER2
Ostatní jména:
|
|
Experimentální: Entrectinib
For patients with a molecular tumor profile that can potentially be targeted by entrectinib. |
NTRK/ ROS1, ALK
Ostatní jména:
|
|
Experimentální: Atezolizumab
For patients with a molecular tumor profile that can potentially be targeted by atezolizumab. |
PD-L1
Ostatní jména:
|
|
Experimentální: Vemurafenib
For patients with a molecular tumor profile that can potentially be targeted by vemurafenib. |
BRAF V600
Ostatní jména:
|
|
Experimentální: Regorafenib
For patients with a molecular tumor profile that can potentially be targeted by regorafenib. |
KIT/BRAF, RET
Ostatní jména:
|
|
Experimentální: Apalutamide
For patients with a molecular tumor profile that can potentially be targeted by apalutamide. |
AR
Ostatní jména:
|
|
Experimentální: Abemaciclib
For patients with a molecular tumor profile that can potentially be targeted by abemaciclib. |
CDK4/6
Ostatní jména:
|
|
Experimentální: Tepotinib
For patients with a molecular tumor profile that can potentially be targeted by tepotinib. |
MET ex14
Ostatní jména:
|
|
Experimentální: Dabrafenib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib. |
RAF
Ostatní jména:
|
|
Experimentální: Trametinib
For patients with a molecular tumor profile that can potentially be targeted by trametinib. |
MEK1, MEK2
Ostatní jména:
|
|
Experimentální: Dabrafenib+Trametinib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination. |
RAF, MEK1, MEK2
Ostatní jména:
|
|
Experimentální: Pemigatinib
For patients with a molecular tumor profile that can potentially be targeted by pemigatinib. |
FGFR2
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Disease control rate
Časové okno: 16 weeks
|
Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD) |
16 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Duration of treatment
Časové okno: 5 years
|
Time on drug |
5 years
|
|
Adverse Events
Časové okno: 5 years
|
Treatment-related grade ≥3 and serious adverse events |
5 years
|
|
Overall response
Časové okno: 5 years
|
Best overall response (defined as patients by CR, PR, SD) |
5 years
|
|
PFS
Časové okno: 5 years
|
Progression free survival |
5 years
|
|
OS
Časové okno: 5 years
|
Overall survival |
5 years
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary podle místa
- Novotvary
- Hematologická onemocnění
- Hemická a lymfatická onemocnění
- Hematologické novotvary
- Sloučeniny síry
- Organické chemikálie
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Amidy
- Indoly
- Sulfonamidy
- Sulfony
- Vemurafenib
- abemaciclib
- dabrafenib
- trametinib
- Atezolizumab
- Cobimetinib
- Regorafenib
- Entrectinib
- Pemigatinib
- Alektinib
- Apalutamid
- Hhantag691
- tepotinib
Další identifikační čísla studie
- FINPROVE
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Investigators plan to share the clinical study report.
Časový rámec sdílení IPD
2026-2027
Kritéria přístupu pro sdílení IPD
Will be made available through European regulatory CTIS programme.
Typ podpůrných informací pro sdílení IPD
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .